Until biomarkers that can predict treatment response emerge, early and aggressive treatment is recommended in lupus nephritis ...
That’s what the autoimmune disease lupus does, 1 and when it strikes, it can cause significant symptoms, including extreme ...
The U.S. Food & Drug Administration (FDA) has granted approval for subcutaneous administration of anifrolumab (SAPHNELO) for ...
Yale researchers have identified CD8+ T cells as a key driver of kidney damage in lupus, challenging the long-standing focus on B cells. The discovery may explain why some patients do not respond to ...
AstraZeneca’s SAPHNELO ® (anifrolumab-fnia) has been approved in the US for self-administration as a once-weekly autoinjector ...
Kidney damage is a serious complication affecting individuals with lupus, an autoimmune disease where immune B cells ...
Researchers are looking into whether a breakthrough cancer therapy is the missing piece that could treat autoimmune diseases.
The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for obinutuzumab for the treatment of systemic lupus erythematosus (SLE). Findings ...
AstraZeneca’s Saphnelo approved in US for subcutaneous self-administration as a new autoinjector to treat systemic lupus erythematosus: Cambridge, UK Tuesday, April 28, 2026, 10 ...
A revolutionary cancer treatment is now being applied to a wide range of autoimmune disorders. Columnist Michael Le Page ...
The FDA has approved a self-administered autoinjector form of anifrolumab for the treatment of systemic lupus erythematosus, ...
Today, Merck KGaA, Darmstadt, Germany, whose U.S. healthcare arm is EMD Serono, announced that the first trial participant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results